Estimated economic costs of overactive bladder in the United States.
about
Anticholinergic drugs versus non-drug active therapies for non-neurogenic overactive bladder syndrome in adultsAnticholinergic drugs versus other medications for overactive bladder syndrome in adultsAnticholinergic drugs versus non-drug active therapies for overactive bladder syndrome in adultsOverview of the Epidemiology of Lower Urinary Tract Dysfunction in South KoreaPharmacoeconomic evaluation of antimuscarinic agents for the treatment of overactive bladderTrospium chloride treatment of overactive bladderTreatment success for overactive bladder with urinary urge incontinence refractory to oral antimuscarinics: a review of published evidencePrevalence, evaluation and management of overactive bladder in primary careMacrovascular Complications and Prevalence of Urgency Incontinence in Japanese Patients with Type 2 Diabetes Mellitus: The Dogo Study.Progression of lower urinary tract symptoms in older men: a community based study.Benign Prostatic Hyperplasia and Male Lower Urinary Tract Symptoms: Epidemiology and Risk Factors.Lifestyle and health factors associated with progressing and remitting trajectories of untreated lower urinary tract symptoms among elderly men.Observational study: daily treatment with a new compound "Tradamixina" plus serenoa repens for two months improved the lower urinary tract symptoms.Darifenacin: a muscarinic M3-selective receptor antagonist for the treatment of overactive bladder.Crucial role of TRPC1 and TRPC4 in cystitis-induced neuronal sprouting and bladder overactivity.The effects of acute and chronic psychological stress on bladder function in a rodent model.Darifenacin: a novel M3 muscarinic selective receptor antagonist for the treatment of overactive bladder.Prevalence and Clinical Features of Detrusor Underactivity among Elderly with Lower Urinary Tract Symptoms: A Comparison between Men and Women.Psychometric Properties of the Korean Version of the Overactive Bladder Questionnaire (OAB-q) in a Korean Population.Tolterodine for the treatment of overactive bladder: a review.Overactive bladder.A review and additional post-hoc analyses of the incidence and impact of constipation observed in darifenacin clinical trialsThe overactive bladder: review of current pharmacotherapy in adults. Part 1: pathophysiology and anticholinergic therapy.Cost implications of antimuscarinic drugs in the treatment of overactive bladder syndrome.Absolute bioavailability of imidafenacin after oral administration to healthy subjectsCurrent and emerging investigational medical therapies for the treatment of overactive bladder.The Burden of Overactive Bladder on US Public HealthIntradetrusor botulinum toxin type A in refractory overactive bladder: A potential future treatment.Pharmacologic management of overactive bladder.Cost-effectiveness of a behavioral intervention for persistent urinary incontinence in prostate cancer patients.Diagnosis and office-based treatment of urinary incontinence in adults. Part one: diagnosis and testingTolterodine for the treatment of overactive bladder.Women's experience with severe overactive bladder symptoms and treatment: insight revealed from patient focus groups.Role of botulinum toxin-A in management of refractory idiopathic detrusor overactive bladder: Single center experienceRole of fesoterodine in the treatment of overactive bladder.Social, economic, and health utility considerations in the treatment of overactive bladder.Characterization of overactive bladder in women in a primary care settingTolterodine extended release is well tolerated in older subjectsOxybutynin extended release for the management of overactive bladder: a clinical review.Fesoterodine for the treatment of urinary incontinence and overactive bladder.
P2860
Q24202075-64E9B7A9-B1D2-4D95-BBFC-932D5310B2A2Q24243527-E4948DFA-04A7-4916-BFA7-62F485343A93Q24243956-0E4BF575-1630-4C43-951C-161CF8ABC4FDQ26744685-B5414BF9-FCF6-4734-B849-1B9DA8EA8B93Q28275473-7B760F69-011C-4BE6-808E-5B851B6F093FQ28308162-20F6F9DC-A356-472C-B6B5-B6E954DAC269Q30906698-EBE158AC-DDBF-4B97-BCAD-FB95BAD89E84Q33402658-CE4FFFA5-F7FB-4D31-B8C6-0020DF57DFB6Q33781106-CDA3F818-D968-48B3-9307-85CE43E1E61AQ33958191-935BA166-FADA-4D66-8397-A03DE8B6D676Q34176834-B25E2E14-CB3C-4F2A-879A-C8C99F96F5CCQ34425753-BFC8A54B-B2D3-454F-A66E-6FF2CD1D9ED3Q34485602-8C6679D0-D31D-4FFE-8AF0-A740AE35D15BQ34575850-AC68893D-0EE0-4ADA-A161-9EEA39DBDF40Q34902996-303A3F01-4A00-4DB5-AAE6-0FDB0606E9A9Q35301066-02E8F47A-1421-4B1D-84D9-0A1C5202D5F8Q35925590-FD247E4E-CA57-4244-82F3-1CD89A5E10C2Q35999333-F52C9F0E-986A-4129-8488-48A83626922DQ36092237-9905B528-74B0-4D36-8173-1446FF010B6FQ36150735-CBD9B499-EAEE-4D2C-82C0-0F7F56E0EA1BQ36226387-49EC6B74-E612-47A5-B220-36AA579F3F2FQ36307893-6384F4B4-BA03-48C8-87F2-889F52E9AD4FQ36428471-68B09673-D0F9-4B8F-B12C-BBD1781F20A3Q36428481-649C95CF-30C6-496D-B29E-93F5497D60D2Q36535862-69645DB2-A908-42BE-85D4-BC4A443129B4Q36568728-0B7B77A5-6540-49F0-9121-C26F4234032CQ36767014-9D38E3E8-6386-49AD-851A-C6D1FCA7C385Q36855832-6136E605-033F-41D9-BBA6-62C5C73D43D8Q37017434-342E446E-1CA0-4483-8912-7BE3C9056760Q37035899-267F5DDF-5B84-4CE5-A5C2-BCD8B0DA0CBBQ37040764-12793661-7377-4559-AEFD-64C24EA9CAC5Q37142090-741E39D2-ED91-4A6C-A353-139EEAB866C5Q37156783-9FBCBF58-BB8B-4CEA-A3BE-F68A0E196428Q37197554-DB48082F-FEB5-487B-A21A-D3C0738E8300Q37283542-56E20627-1C33-4AD9-861A-BF07C584B40DQ37283547-14A60ED6-1922-4B87-B016-20FECE9F201BQ37283712-6C692CB5-5446-4E34-B6BD-F6CB6B51B562Q37332901-C23F23FE-D6F4-4E44-8CB5-81ADB4309B1CQ37403203-A3536059-B2A7-40B6-B618-94D93D088684Q37429813-20640330-02FC-4190-A371-177AE8654CA9
P2860
Estimated economic costs of overactive bladder in the United States.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh-hant
name
Estimated economic costs of overactive bladder in the United States.
@en
Estimated economic costs of overactive bladder in the United States.
@nl
type
label
Estimated economic costs of overactive bladder in the United States.
@en
Estimated economic costs of overactive bladder in the United States.
@nl
prefLabel
Estimated economic costs of overactive bladder in the United States.
@en
Estimated economic costs of overactive bladder in the United States.
@nl
P2093
P1433
P1476
Estimated economic costs of overactive bladder in the United States.
@en
P2093
Amy Piancentini
Judith D Bentkover
Kristi LeBlanc
Steve Z Zhou
Teh-Wei Hu
Timothy L Hunt
Todd H Wagner
Walter F Stewart
P304
P356
10.1016/S0090-4295(03)00009-8
P407
P577
2003-06-01T00:00:00Z